Lead Product(s) : HLIM
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trials to Assess the Efficacy and Safety of HLIM
Details : HLIM is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Tract Infections.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 01, 2019
Lead Product(s) : HLIM
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable